低剂量CT引导的解剖标准化用于淀粉样蛋白PET定量
本研究评估低剂量CT替代MRI进行解剖标准化计算Centiloid(CL)量表的准确性,纳入24例可能或很可能阿尔茨海默病患者的18F-flutemetamol淀粉样蛋白PET图像。结果显示CLCT较CLMRI轻度但显著低估(均值±标准差,-1.7±2.4;p<0.002),两者高度相关(r=0.998,p<0.001),结论认为低剂量CT可替代MRI用于CL量表计算,尽管存在轻度低估。
要点
- CLCT较CLMRI轻度但显著低估(均值±标准差,-1.7±2.4;p<0.002)。
- CLCT与CLMRI高度相关(r=0.998,p<0.001),线性回归方程为CLMRI=1.027×CLCT+0.762。
- 低剂量CT可替代MRI用于淀粉样蛋白PET的CL量表计算,但存在轻度低估。
核心结论
- PET/CT的低剂量CT可替代MRI用于淀粉样蛋白PET计算CL量表时的解剖标准化,尽管会出现轻度低估。
研究设计与样本
- 本研究纳入24例可能或很可能阿尔茨海默病患者的18F-flutemetamol淀粉样蛋白PET图像,分别使用3D T1加权MRI和PET/CT的低剂量CT进行解剖标准化并计算CL量表,比较CLMRI与CLCT,并探究基于CT与基于MRI的标准化解剖图像的区域差异。
- 试验注册:日本临床试验注册库,jRCTs031180321,注册日期2019年3月18日。
主要发现
- Bland-Altman图显示CLCT较CLMRI轻度但显著低估(均值±标准差,-1.7±2.4;p<0.002),95%一致性界限为-2.8至-0.7。
- Pearson相关分析显示CLCT与CLMRI高度显著相关(r=0.998,p<0.001),线性回归方程为CLMRI=1.027×CLCT+0.762。
- Spearman相关分析未发现CLMRI与CLCT的差值与CL负荷之间存在显著关联(ρ=-0.389,p=0.060)。
- CLCT的轻度低估可能源于以CT为基础解剖标准化的PET图像中小脑作为参考区时摄取略高于以MRI为基础的图像。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Centiloid (CL) scaling has become a standardized quantitative measure in amyloid PET because it facilitates the direct comparison of results across institutions, even when different analytical methods or tracers are used. Standard volumes of interest must be used to calculate the CL scale after the anatomic standardization of amyloid PET images using coregistered MRI; if the MRI is unavailable, the CL scale cannot be accurately calculated. This study sought to determine the substitutability of low-dose CT, which is used to correct PET attenuation in PET/CT equipment, by evaluating the measurement accuracy when low-dose CT is used as an alternative to MRI in the calculation of the CL scale. Amyloid PET images obtained using 18F-flutemetamol from 24 patients with possible or probable Alzheimer's disease were processed to calculate the CL scale using 3D T1-weighted MRI and low-dose CT of PET/CT. CLMRI and CLCT were, respectively, defined as the use of MRI and CT for anatomic standardization and compared. Regional differences in the CT-based and MRI-based standardized anatomic images were also investigated. TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCTs031180321 (registered 18 March 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031180321 ). RESULTS: A Bland-Altman plot showed that CLCT was slightly but significantly underestimated (mean ± standard deviation, - 1.7 ± 2.4; p < 0.002) compared with CLMRI. The 95% limits of agreement ranged from - 2.8 to - 0.7. Pearson correlation analysis showed a highly significant correlation of r = 0.998 between CLCT and CLMRI (p < 0.001). The linear regression equation was CLMRI = 1.027 × CLCT + 0.762. In a Bland-Altman plot, Spearman correlation analysis did not identify a significant association between the difference in CLMRI versus CLCT and CL load (ρ = - 0.389, p = 0.060). This slight underestimation of CLCT may derive from slightly higher uptake when the cerebellum is used as a reference area in CT-based anatomically standardized PET images versus MRI-based images. CONCLUSIONS: Low-dose CT of PET/CT can substitute for MRI in the anatomic standardization used to calculate the CL scale from amyloid PET, although a slight underestimation occurs.
引用
- Matsuda H, Yamao T, Shakado M, et al. Amyloid PET quantification using low-dose CT-guided anatomic standardization. EJNMMI Res. 2021. PMID: 34905145. doi:10.1186/s13550-021-00867-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。